Given that there have not been established criteria for advanced EMPD and the patient refused to accept chemotherapy regimens due to adverse events, we recommended anti–Her-2 drug combined immunotherapy as first-line treatment and the regimens gained the patient’s informed consent (Supplementary Material). The gene discussed is ERBB2; the disease is extramammary Paget disease.